{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T10:22:42Z","timestamp":1768645362864,"version":"3.49.0"},"reference-count":30,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R15CA249788"],"award-info":[{"award-number":["R15CA249788"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["SC2GM130470"],"award-info":[{"award-number":["SC2GM130470"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH SC2 award","doi-asserted-by":"publisher","award":["R15CA249788"],"award-info":[{"award-number":["R15CA249788"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH SC2 award","doi-asserted-by":"publisher","award":["SC2GM130470"],"award-info":[{"award-number":["SC2GM130470"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Despite the successes of immunotherapy, melanoma remains one of the deadliest cancers, therefore, the need for innovation remains high. We previously reported anti-melanoma compounds that work by downregulating spliceosomal proteins hnRNPH1 and H2. In a separate study, we reported that these compounds were non-toxic to Balb\/C mice at 50 mg\/kg suggesting their utility in in vivo studies. In the present study, we aimed to assess the efficacy of these compounds by testing them in A375 cell-line xenograft in nude athymic mice. Animals were randomized into four groups (n = 12\/group): 10 mg\/kg vemurafenib, and 25 mg\/kg 2155-14 and 2155-18 thrice a week for 15 days along with a control group. The results revealed that both 2155-14 and 2155-18 significantly decreased the growth of A375 tumors, which was comparable to vemurafenib. These results were confirmed by tumor volume, weight, and histopathological examination. In conclusion, these results demonstrate the therapeutic potential of targeting spliceosomal proteins hnRNPH1 and H2.<\/jats:p>","DOI":"10.3390\/biom13091276","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T08:58:54Z","timestamp":1692694734000},"page":"1276","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel Anti-Melanoma Compounds Are Efficacious in A375 Cell Line Xenograft Melanoma Model in Nude Mice"],"prefix":"10.3390","volume":"13","author":[{"given":"Sadeeshkumar","family":"Velayutham","sequence":"first","affiliation":[{"name":"College of Pharmacy, Nova Southeastern University, 3321 College Avenue, Fort Lauderdale, FL 33314, USA"},{"name":"Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, 3321 College Avenue, CCR r.605, Fort Lauderdale, FL 33314, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Seerattan","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Queens College, 65-30 Kissena Boulevard, Flushing, NY 11367, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maab","family":"Sultan","sequence":"additional","affiliation":[{"name":"Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, 3321 College Avenue, CCR r.605, Fort Lauderdale, FL 33314, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trisha","family":"Seal","sequence":"additional","affiliation":[{"name":"Halmos College of Arts and Sciences, Nova Southeastern University, 3301 College Avenue, Fort Lauderdale, FL 33314, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samaya","family":"Danthurthy","sequence":"additional","affiliation":[{"name":"Honors College, Nova Southeastern University, 8000 N Ocean Dr., Dania Beach, FL 33004, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baskaran","family":"Chinnappan","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Nova Southeastern University, 3321 College Avenue, Fort Lauderdale, FL 33314, USA"},{"name":"Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, 3321 College Avenue, CCR r.605, Fort Lauderdale, FL 33314, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Landi","sequence":"additional","affiliation":[{"name":"Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, 3321 College Avenue, Fort Lauderdale, FL 33314, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn","family":"Pearl","sequence":"additional","affiliation":[{"name":"Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, 3321 College Avenue, Fort Lauderdale, FL 33314, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aveta","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Queens College, 65-30 Kissena Boulevard, Flushing, NY 11367, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiran S. M.","family":"Smalley","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Zaias","sequence":"additional","affiliation":[{"name":"Division of Comparative Pathology, University of Miami, 1501 NW 10th Ave, Miami, FL 33136, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8218-6440","authenticated-orcid":false,"given":"Jun Yong","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Queens College, 65-30 Kissena Boulevard, Flushing, NY 11367, USA"},{"name":"Ph.D. Programs in Chemistry and Biochemistry, The Graduate Center of the City University of New York, 365 5th Ave, New York, NY 10016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitriy","family":"Minond","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Nova Southeastern University, 3321 College Avenue, Fort Lauderdale, FL 33314, USA"},{"name":"Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, 3321 College Avenue, CCR r.605, Fort Lauderdale, FL 33314, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society (2023). Key Statistics for Melanoma Skin Cancer, American Cancer Society."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.det.2019.05.001","article-title":"Systemic Therapies for Advanced Melanoma","volume":"37","author":"Bomar","year":"2019","journal-title":"Dermatol. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"s663","DOI":"10.1016\/S0959-8049(16)31820-2","article-title":"3301 Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (Vem) as First-Line Therapy in Patients (Pts) with Unresectable or Metastatic","volume":"51","author":"Robert","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.33594\/000000164","article-title":"A Novel Probe for Spliceosomal Proteins that Induces Autophagy and Death of Melanoma Cells Reveals New Targets for Melanoma Drug Discovery","volume":"53","author":"Palrasu","year":"2019","journal-title":"Cell Physiol. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1021\/jm4019542","article-title":"Novel pyrrolidine diketopiperazines selectively inhibit melanoma cells via induction of late-onset apoptosis","volume":"57","author":"Tack","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Velayutham, S., Seal, T., Danthurthy, S., Zaias, J., Smalley, K.S.M., and Minond, D. (2023). In Vivo Acute Toxicity Studies of Novel Anti-Melanoma Compounds Downregulators of hnRNPH1\/H2. Biomolecules, 13.","DOI":"10.3390\/biom13020349"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11661","DOI":"10.1021\/jacs.8b05366","article-title":"Differential Conformational Dynamics Encoded by the Linker between Quasi RNA Recognition Motifs of Heterogeneous Nuclear Ribonucleoprotein H","volume":"140","author":"Penumutchu","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103580","DOI":"10.1016\/j.drudis.2023.103580","article-title":"RNA-binding proteins in cancer drug discovery","volume":"28","author":"Bertoldo","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/1535-7163.MCT-08-1026","article-title":"Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A","volume":"8","author":"Kuznetsov","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.18632\/oncotarget.598","article-title":"Tumor suppression by small molecule inhibitors of translation initiation","volume":"3","author":"Chen","year":"2012","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-13-0485","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors","volume":"19","author":"Eskens","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10637-013-0046-5","article-title":"A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors","volume":"32","author":"Hong","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"12297","DOI":"10.18632\/oncotarget.3655","article-title":"Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy","volume":"6","author":"Cirenajwis","year":"2015","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ra7","DOI":"10.1126\/scisignal.2003057","article-title":"Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells","volume":"6","author":"Beck","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00439-016-1683-5","article-title":"The hnRNP family: Insights into their role in health and disease","volume":"135","author":"Geuens","year":"2016","journal-title":"Hum. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"682859","DOI":"10.3389\/fonc.2021.682859","article-title":"HNRNPH1 Is a Novel Regulator Of Cellular Proliferation and Disease Progression in Chronic Myeloid Leukemia","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Takahashi, K., Fujiya, M., Konishi, H., Murakami, Y., Iwama, T., Sasaki, T., Kunogi, T., Sakatani, A., Ando, K., and Ueno, N. (2020). Heterogenous Nuclear Ribonucleoprotein H1 Promotes Colorectal Cancer Progression through the Stabilization of mRNA of Sphingosine-1-Phosphate Lyase 1. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124514"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/15476286.2015.1138030","article-title":"High-throughput analyses of hnRNP H1 dissects its multi-functional aspect","volume":"13","author":"Uren","year":"2016","journal-title":"RNA Biol."},{"key":"ref_24","unstructured":"Diez, J., Rajendrarao, S., Baajour, S.A., Sripadhan, P., Spicer, T.P., Scampavia, L.D., and Minond, D. (2023, January 15\u201319). Downregulation of Spliceosomal Proteins hnRNPH1 and H2 in WM266-4 Melanoma Cells Induces Immune Signaling. Proceedings of the Annual Meeting of American Association of Cancer Research, Orlando, FL, USA."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"12322","DOI":"10.1038\/s41598-020-69082-z","article-title":"Immune expression signatures as candidate prognostic biomarkers of age and gender survival differences in cutaneous melanoma","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e000150","DOI":"10.1136\/esmoopen-2016-000150","article-title":"Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer","volume":"2","author":"Kitano","year":"2017","journal-title":"ESMO Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1235107","DOI":"10.1080\/2162402X.2016.1235107","article-title":"PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome","volume":"5","author":"Obeid","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2017.06.016","article-title":"IFNgamma-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment","volume":"170","author":"Nirschl","year":"2017","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1017\/S0016672300010168","article-title":"\u2018Nude\u2019, a new hairless gene with pleiotropic effects in the mouse","volume":"8","author":"Flanagan","year":"1966","journal-title":"Genet. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cell.2020.12.031","article-title":"Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer","volume":"184","author":"Bowling","year":"2021","journal-title":"Cell"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/9\/1276\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:39:12Z","timestamp":1760128752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/9\/1276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["biom13091276"],"URL":"https:\/\/doi.org\/10.3390\/biom13091276","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]}}}